WG
MYGN icon

Winton Group’s Myriad Genetics MYGN Stock Holding History

Winton Group’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-31,500
Closed -$142K – 1385
2026
Q1 		$142K Buy
31,500
+18,000
+133% +$93.8K 0.01% 1017
2025
Q4 		$83K Buy
+13,500
New +$97.9K ﹤0.01% 883
2019
Q4 		– Sell
-27,731
Closed -$794K – 1701
2019
Q3 		$794K Buy
+27,731
New +$808K 0.01% 932

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Winton Group's MYGN Position: Q2 2026 in Review

Winton Group sold out of Myriad Genetics (MYGN) in Q2 2026, closing a stake of 31,500 shares — an estimated $142K sold.

Winton Group first reported a position in MYGN in Q3 2019 and held it in 3 quarters. The position peaked at $794K in Q3 2019. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Winton Group reported no remaining Myriad Genetics position as of Q2 2026 after selling out during the quarter.
  • Winton Group sold 31,500 Myriad Genetics shares in Q2 2026, an estimated $142K.
  • Winton Group first reported a position in Myriad Genetics in Q3 2019 and held it in 3 quarters.
  • Winton Group's Myriad Genetics position peaked at $794K in Q3 2019.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.